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Abstract
Glioblastoma multiforme (GBM) tumors are the most common malignant primary brain tumors in
adults. Although many GBM tumors are believed to be caused by self-renewing, glioblastoma-
derived stem-like cells (GSCs), the mechanisms that regulate self-renewal and other oncogenic
properties of GSCs are only now being unraveled. Here we showed that GSCs derived from GBM
patient specimens express varying levels of the transcriptional repressor REST, suggesting
heterogeneity across different GSC lines. Loss- and gain-of-function experiments indicated that
REST maintains self-renewal of GSCs. High REST-expressing GSCs (HR-GSCs) produced
tumors histopathologically distinct from those generated by low REST-expressing GSCs (LR-
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GSCs) in orthotopic mouse brain tumor models. Knockdown of REST in HR-GSCs resulted in
increased survival in GSC-transplanted mice and produced tumors with higher apoptotic and
lower invasive properties. Conversely, forced expression of exogenous REST in LR-GSCs
produced decreased survival in mice and produced tumors with lower apoptotic and higher
invasive properties, similar to HR-GSCs. Thus, based on our results, we propose that a novel
function of REST is to maintain self-renewal and other oncogenic properties of GSCs and that
REST can play a major role in mediating tumorigenicity in GBM.
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Introduction
Glioblastoma multiforme (GBM) tumors are the most common malignant primary brain
tumors in adults 1–3 However, despite decades of basic science and clinical research, the
outcome for GBM patients remains dismal, with average median survival of only 12–16
months4–15. The lack of progress in GBM research can be attributed to the highly
heterogeneous, invasive, necrotic, and chemotherapy- and radiation-resistant nature of GBM
tumor cells16. Thus, even after aggressive multimodal therapy, the invading tumor cells
often survive and cause tumor relapse. The generation of invaluable animal models have
provided new insights into GBM biology and alternate therapeutic approaches17–19. In
addition, the recent advent of the “cancer stem cell” hypothesis has brought a new
perspective to our understanding of GBM biology and therapy16, 20–23. According to this
hypothesis, tumors contain stem-like cells, which have the capacity for long-term self-
renewal. This hypothesis further proposes that stem-like cells are the main cancer-initiating
cells due to their long-term self-renewal capacity. However, the mechanisms that lead to
self-renewal and tumorigenicity in glioblastoma-derived stem-like cells (GSCs) are still
unclear.
The transcriptional repressor REST was originally discovered as a repressor of many
neuronal differentiation genes in non-neural cells and results derived from Rest mutant mice
showed that it was indeed a repressor of neurogenesis24–26. However, more recent genome-
wide analysis revealed that REST can bind to the chromatin of more than a thousand genes
and can potentially affect many biological processes of different tissue types27. Our previous
studies indicated that REST maintains self-renewal of embryonic stem cells28 and that this
role of REST was dependent on the specific cell line as well as the cellular environment
(unpublished data). More recently, REST was found to maintain stemness of normal adult
neural stem cells 29 . Our previous studies indicated that REST is involved in
medulloblastoma tumorigenesis, in which it functions by blocking differentiation of
neuronal stem/progenitor cells30–32. Thus, we reasoned that REST might have a critical role
in maintaining self-renewal and other oncogenic properties of GSCs. Our studies indicate
that REST indeed regulates such functions in GSCs. Our studies also suggest that targeting
REST can potentially represent a novel therapeutic strategy in GBM.
Kamal et al. Page 2















GSCs used in this study were obtained by acute cell dissociation of human glioblastoma
multiforme (GBM) surgical specimens from patients treated at The University of Texas MD
Anderson Cancer Center, Houston, Texas, as described previously33–38. The specific HR-
GSC1, HR-GSC2 and/or LR-GSC lines have been described previously33–38. These cell
lines were maintained under proliferation conditions in Dulbecco’s modified Eagle’s
medium (DMEM)/F12 supplemented with B27 1:50 (Invitrogen), 20 ng/ml EGF (Sigma),
and 20 ng/ml bFGF as neural stem cell–permissive medium, according to procedures
described elsewhere39, 40. These cell lines form neurospheres and demonstrate the ability to
express multiple lineage markers and reliably form tumors that recapitulate many of the
pathological features of the original tumor after orthotopic xenografting36, 37, 41.
Immunofluorescence and TUNEL Assay
Cells were fixed with 4% paraformaldehyde (PFA) in PBS for 15 minutes. After washing
with PBS, cells were blocked with 4% goat serum and 0.3% Triton-X for 1 hour at room
temperature. Primary antibodies were added overnight at 4°C, rabbit anti-REST (Sigma,
1:100), mouse anti-REST (1:100), Sox-2 (Stemgent, 1:50), rabbit anti-YKL40 (Quidel,
1:500). After washing with PBS, cells were incubated with Alexa fluor secondary antibodies
(Invitrogen) for 1 hour at room temperature. Cells were mounted with mounting media
containing 4,6 diamino-2-phenylindole (DAPI) (Vector Laboratories) and photographed
using a Nikon TE2000 controlled with Metamorph software (Molecular Devices).
Paraffin sections were hydrated through alcohol grades after clearing with CitriSolv (Fisher
Scientific). Antigen retrieval was performed with citrate buffer at 90°C for 20 minutes.
Sections were blocked with 4% goat serum followed by human specific primary antibody
(Nestin 1:200 (Millipore)) overnight at 4°C. After washing twice with PBS sections were
incubated with secondary antibodies followed by mounting with DAPI. In vivo TUNEL
Assay was conducted as per manufacturer’s recommendations and positive cells were
counted from 10 different fields (Roche cat # 11684817910).
Neurosphere and self-renewal assay
For GSCs, neurosphere assay was done as previously described33–38. In brief, cells were
dissociated into single cell suspensions, 10 cells per well for self renewal assay for multiple
generations or 100 cells per well self renewal for single generation were seeded in 96-well
plates, and the number of neurospheres was counted after 15 days. For serial neurosphere
assay, cells were collected after the first passage and dissociated into single cells and plated
at the same density as the first passage.
In vitro invasion assay
Control and Rest altered lines were counted and 5×105 cells were seeded into the upper
compartment of either the invasion or control chambers, as chemo-attractant 10%FBS
containing media was added to the lower chamber. Cells were incubated for 24 hrs. The
nonadherent cells were removed by washing with PBS and the noninvading cells were
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removed by cotton swabs. The control and invasion membranes were then fixed with 100%
Methanol and stained with crystal violet. Cells were counted under the microscope and a
ratio of invading cells on the matrigel matrix to invasive cells on the control membranes of
the control versus the Rest altered lines was compared.
Cell transfections and transductions
Loss-of-function experiments—Stable knockdown of REST in GSCs was done using
Mission-lentiviruses expressing short hairpin RNA (shRNA) (Sigma), either non-targeting
shRNA (shNT) as control or targeting REST (shRest). Cells were incubated the day prior to
transduction with 8 µg/ml hexadimethrine bromide. Cells were then incubated with the virus
particles at one multiplicity of infection (1MOI) in normal proliferation media for 48 hours.
Cells were puromycin (1.5ug/ml) selected. Five individual clones for each line were
selected, cultured and REST knockdown efficiency was determined by western blot
analysis. The clone with maximum knockdown for each line (shRest construct #1 for HR-
GSC1: 42% knockdown; shRest construct #3 for HR-GSC2: 70% knockdown) was selected
for further experimentation.
Gain-of-function experiments—GSCs were transfected with plasmids expressing a
control vector, or Rest using the the Amaxa nucleofector kit. In brief, 4×106 cells were
suspended in 90 µl of nucleofector solution with REST or control plasmids and then
transfected using an Amaxa transfection device. Cells were puromycin (1.5ug/ml) selected
and REST over expression was confirmed by western blot analysis.
RNA preparation and qRT-PCR
Total RNA prepared using Trizol (Invitrogen) according to the manufacturer’s instructions.
Approximately 500 ng total RNA was used as a template for cDNA synthesis using the
Verso cDNA kit (Thermo-Scientific). Real-time PCR was done using SYBR green master-
mix (Applied Biosystems) as per the manufacturer’s instructions. All real-time PCR
experiments were done on an ABI7900HT sequence detection system (Applied Biosystems).
Genome-wide expression analysis of GSCs with loss- and gain-of-function manipulations
Total RNA was used and Affymetrix HG-133 Plus 2.0 whole genome microarrays were
performed (LC sciences, Houston) for two HR-GSCs and one LR-GSC plus the
corresponding control lines. Genes with differential fold expression in HR- versus LR-GSCs
were determined using the Agilent GeneSpring GX 11.5 software. Robust Multiarray
Average (RMA) was used for normalization and genes greater than 1.5 fold differentially
expressed were included to determine gene function and disease ontologies using Ingenuity
Pathway Analysis (IPA, www.ingenutiy.com).
Western blot procedures
Whole cell extracts were prepared from cell lines and 30 µg protein was loaded on gradient
SDS-PAGE gel (Pierce). Then proteins were electrophoretically transferred to nitrocellulose
membranes. The membranes were probed with the following antibodies: rabbit anti-REST
(1:1000, Upstate), mouse anti-Sox2 (1:350 R&D), and rabbit anti-Nestin (Millipore,
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1:10,000), mouse anti Bmi-1 (Millipore, 1:500), and goat anti-YKL40 (Santacruz, 1:200).
Mouse anti-actin (1:10,000, Sigma) was used as the internal control. The membranes were
incubated with the primary antibodies overnight before they were incubated with
corresponding fluorescent-labeled secondary antibodies (1:15000, Licor) for 1 hour at room
temperature. The protein-antibody complexes were visualized by scanning the membrane
using the Odyssey detection system (Li-Cor Biosciences).
Proliferation assays
Proliferation assays for HR-GSC1 and HR-GSC2 cell lines were done using colorimetric
BrdU cell proliferation assay kit (Roche 11647229-01).The assay was performed according
to manufacturer’s instructions. In short GSC 1 or GSC 2 cells were seeded at 3000 cells per
well in a 96 well plate. Allowed them to grow for overnight and incubated with BrdU
labeling agent for 24 hours. Cells were fixed for 30min and incubated with Anti-BrdU for 2
hours and the substrate was added and on color development, colorimetric measurements
were performed at 492nm.
Intracranial tumorigenicity assay
Intracranial transplantation of GSCs into nude male mice was done as described
previously41. A total of 56 animals (7 animals/treatment condition) were used. To
standardize GSC transplantation into nude mice brain, a guide-screw system was implanted
2.5mm lateral and 1mm anterior to the bregma accepting a 26 gauge Hamilton syringe.
GSCs cultured were collected and dissociated into single cells. 50,000 cells (or 5,000 cells
for Supplementary Fig. 2) in 5ul of media were simultaneously injected using an automated
syringe pump (Harvard Apparatus). Animals were carefully monitored for survival.
Statistical Analysis
Values are reported as mean+/− standard error of means. Microsoft Excel 2010 and SPSS
(IBM) software was used to conduct t-test or ANOVA for each of the experiments.
Microarray data was analyzed with Agilent GeneSpring GX11.5 and the Genepattern suite
(Broad Institute).
Results
Patient derived glioblastoma stem cells show varying levels of the REST protein
To understand the role of REST in GBM, we quantified REST protein expression in ten
patient-derived GSC lines. These lines showed varying levels of REST protein with several
fold differences between the lines (Fig. 1A). High REST expression (HR-GSCs) coincided
with high levels of Sox2, a known neural stem cell self-renewal regulator42, 43, whereas low-
REST expression (LR-GSCs) with low levels of Sox2, suggesting that REST plays a role in
self-renewal of GSCs. Interestingly, only one of the GSC lines expressed YKL40, a
mesenchymal marker9. To further understand the regulation of REST expression in GSCs,
we measured the Rest transcript levels using real time RT-PCR. Comparison of the relative
levels of REST protein and Rest transcript levels (Fig. 1B, left panel) and a scatter plot (Fig.
1B, right panel) are shown. The data indicated that the transcript levels did not correlate with
the REST protein levels (correlation coefficient =0.04, Fig. 1B). To investigate the lack of
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correlation between protein and RNA levels, we treated GSCs with the proteasomal inhibitor
(MG132) for 24 hours. Our results indicated significant REST protein accumulation in most
of the 11 different GSC lines after MG132 treatment compared to the control DMSO
treatment (Figure 1C). These results strongly suggested that REST expression is controlled
mainly at the protein degradation level in GSCs, similar to what was observed in other cell
types26, 44, 45.
REST protein levels correlate with expression of stemness markers and neurosphere
formation capacity of GSCs
We selected two GSC lines with high levels of REST, HR-GSC1 and HR-GSC2 (GSC11
and GSC23, respectively), and one line with low levels of REST, LR-GSCs (GSC20), for
further characterization by Western blotting (Fig. 2A) and double-immunofluorescence (Fig.
2B) analysis. As shown, both HR-GSC lines, compared to LR-GSCs, showed higher
expression of the neural stemness markers Nestin, Sox2, and Bmi1, and absence YKL-40.
These findings further confirmed the association of REST with stemness markers of GSCs.
To determine if high levels of REST in GSCs corresponded to increased functional stem-like
properties, we measured their self-renewal efficiency using neurosphere assays. Our results
showed greater neurosphere formation ability of both HR-GSC1 and HR-GSC-2 compared
to LR-GSCs (Fig. 2C). Thus, our data indicated that high REST expression is associated
with high stemness of GSCs both at marker and functional levels.
REST maintains self-renewal of GSCs
To determine the functional role of REST in GSCs, we generated stable lines expressing
either shNT control or shRest in HR-GSC1 and HR-GSC2. As shown in Figures 3A and 3B,
Western blot analysis confirmed REST protein knockdown in the shRest clones in both HR-
GSC lines. The knockdown of REST corresponded to increased expression of neuronal β-
tubulin, a direct target gene of Rest46, 47, indicating that shRest caused a functional REST
knockdown. The loss of REST also produced concomitant loss of the stemness regulator
Sox2. To determine whether loss of REST resulted in functional loss of stem like properties
of GSCs, we performed self-renewal assays in both HR-GSCs lines. Our results showed that
loss of REST resulted in decreased self-renewal in both the high REST lines over multiple
passages (Supplementary Figs. 1A for HR-GSC1 and Fig. 1B for HR-GSC2), indicating that
REST maintains self-renewal in both HR-GSC lines.
To further establish the role of REST in GSCs, we performed complementary experiments
in which we transfected LR-GSCs with expression vectors encoding either non targeting
control or Rest, confirmed the increased REST protein expression by Western blot and
determined the cells’ self-renewal capacity (Fig. 3C). As shown, higher REST expression
produced lower expression of its target gene neuronal beta-tubulin and caused a significant
increase in self-renewal. As expected from the loss-of-function experiments, additional
REST caused an increase in the expression of Sox2 levels (Supplementary Fig. 2). Thus,
taken together, these results showed that REST maintains self-renewal of GSCs.
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HR-GSCs and LR-GSCs produce distinct brain tumors in mice
To determine the tumor-producing properties of the HR- and LR-GSCs, we transplanted
HR-GSC1 and LR-GSC cells (5×104 cells) into the brains of nude mice and performed
mouse survival assays (Fig. 4A) and histopathological examination of the resultant tumors
(Fig. 4B). HR-GSC1 cells produced shorter survival in mice compared with LR-GSCs. This
corresponded to their respective self-renewal capacity (Fig. 2C). While both HR- and the
LR-GSC lines produced tumors, HR-GSC1 tumors morphologically showed a marked
difference in growth pattern when compared with the LR-GSC tumors. The HR-GSC1
tumors were more diffusely infiltrative than the LR-GSC tumors, which grew as relatively
circumscribed expansive masses.
REST regulates survival in orthotropic mouse model
We performed loss-of-function experiments, in which we transplanted 5×104 cells of the
stable lines of HR-GSC1 (Fig. 4C) and HR-GSC2 (Fig. 4D) expressing either shRest or
shNTinto the brains of nude mice and assayed for their survival. Under these conditions,
shRest treatment, as compared with shNT treatment, increased the survival of tumor-bearing
mice. Although the effect in mouse survival was statistically significant, it was not robust
and perhaps points to the notion that survival depended on multiple factors. To further
confirm that these experiments were performed under conditions, in which the survival
correlated with the number of cells injected, we compared the survival of mice harboring
HR-GSC1 cells expressing either shRest or shNT and either 5×104 (Fig. 4C) or 5×103
(Supplementary Fig. 3) per mouse. All mice bearing shNT control cells died within 64 days
for 5×104 cells compared to within 112 days for 5×103 cells, indicating that survival
corresponded inversely to the number of tumor cells transplanted. Thus, these results
suggest that by regulating self-renewal in GSCs, REST expression also correlated with
survival of GSC tumor-bearing mice.
To further establish the control of survival by REST, we performed gain-of-function
experiments, in which we transplanted LR-GSCs expressing REST that we previously found
to express higher levels of the REST protein, lower levels of its target gene, neuronal β-
tubulin, and concomitant higher self-renewal ability into the brains of nude mice. We then
assayed for survival (Fig. 4E). As shown, the addition of exogenous REST, compared with
that of non-targeting control, to LR-GSCs caused decreased survival in tumor-bearing mice.
Thus, REST controls survival in mice bearing GSC-mediated brain tumors
REST suppresses apoptosis in GSC-mediated tumors
To determine if the tumorigenic effects of REST in mouse brain tumors were partly
regulated by promoting GSC survival, we analyzed our orthotopic mouse tumor sections for
apoptosis using TUNEL assays. The data showed increased cell death upon REST
knockdown in both HR-GSC lines (Fig. 5A and Fig. 5B) and, conversely, decreased cell
death upon expression of exogenous REST in the LR-GSC line (Fig. 5C). Quantification of
the TUNEL assay is shown in Fig. 5D. The in vivo TUNEL staining was concordant with
the BrdU-incorporation in cultured cells and showed a decrease in cell proliferation for the
two HR-GSC lines upon REST knockdown (Supplementary Fig. 4). These results indicated
that REST suppresses apoptosis in GSC tumors.
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Genome-wide mRNA expression analysis reveals further potential oncogenic properties of
REST
Because REST regulates numerous genes, it is likely that REST controls tumorigenicity of
GSCs at multiple regulatory points. To determine what pathways could be affected by REST
alteration in GSCs, in addition to self-renewal and cell viability, we compared genome-wide
mRNA expression profiling of the six GSC lines that we characterized above: HR-
GSC1+shNT, HR-GSC1+shRest, HR-GSC2+shNT, HR-GSC2+shRest, LR-GSC+GFP, and
LR-GSC+Rest. We identified 301 genes that were more than 1.5 fold differentially
expressed across the HR- versus the LR-GSC lines. We then identified core biological
pathways and cellular functions associated with REST expression using the Ingenuity
Pathway Analysis (Table 1). The pathways involving cellular movement, cellular assembly
and organization, cellular development, cell-to-cell signaling and interaction, and cellular
growth and proliferation were most significantly associated with REST.
REST regulates invasion of GSC-mediated orthotopic tumors
Since the genome-wide results suggested REST to play a major role in cellular movement,
we further investigated whether REST regulated invasion of GSCs using in vitro invasion
assays. Our data showed a statistically significant decrease of invasion in the two HR-GSC
lines upon REST knock down with HR-GSC1 showing comparatively higher degree of
infiltration than HR-GSC2 (Supplementary Fig. 5).
To further establish the role of REST in GSC-mediated invasion, we re-examined the tumor
sections generated during orthotopic mouse experiments described in Fig 4 by staining the
tumor sections with a human nestin antibody to distinguish the human tumor-derived cells
from the surrounding mouse cells (Fig. 6A – 6C)48. This approach helps in visualizing the
injected human cells in the midst of mouse brain cells present in the mouse xenograft tumors
but cannot determine the cellular status of the injected cells, such as their stemness or
differentiation properties. Our results indicated that the shNT-treated HR-GSC1 and HR-
GSC2 lines showed very high degree of migration with cell invasion to the pial surface from
the core of the tumor. In contrast, the corresponding shRest-treated cells showed a decreased
migratory phenotype with a circumscribed tumor growth, where cells rarely reached the pial
surface. In the complementary experiment, exogenous REST expression in LR-GSCs
resulted in a diffuse tumor growth and significant increase of cellular invasion compared to
the control cells, in which GFP was expressed. Remarkably, the expression of additional
REST in LR-GSCs converted the tumors such that they were similar to HR-GSCs. Taken
together, these results suggest a major in vitro and in vivo role of REST in regulating tumor
phenotype and invasion in GSCs.
Discussion
Here we show that REST promotes oncogenic properties of GSCs with respect to self-
renewal, cellular viability, and invasion and affects survival in mice bearing GSC-xenograft
tumors. Our work does not reflect the GBM tumor, which will presumably contain many
other types of cells than just the GSCs. Previously, we found that REST, which is also over-
expressed in a major subtype of human medulloblastoma tumors that are mostly in the
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neuronal pathway, caused tumorigenesis by blocking the differentiation of cerebellar stem/
progenitor cells30, 31. Thus, these results suggest that the conservation of stemness through
REST contributes to both neuronal and glial tumors and that deregulation of normal REST
expression is a major factor in producing these tumors. Our results also indicate that REST
expression in GSCs is mainly regulated at the protein degradation level suggesting that
patient outcome should be determined based on REST expression at the protein, and not
transcript, levels. Thus, the public datasets, which are based on the transcript levels, cannot
be used to determine the prognostic values of the HR- versus LR-GBM patient population.
Our results indicate that expression of exogenous REST in LR-GSCs produce more invasive
tumors in the mouse brain. The mechanism by which REST regulates invasive properties is
unclear. Neural stem cells carrying exogenous genes were found to specifically target mouse
intracranial glioma tumors either when transplanted at a site distant from the tumor or
injected into the tail veins, providing a promising means of delivery of therapeutic
molecules to the tumor49. The targeting activity of the NSCs is presumably regulated by
cell-cell and cell-microenvironment interactions. Whether the high-level expression of
REST in HR-GSCs would affect the tumor-targeting process of NSCs is unknown. We are
currently exploring ways to answer these questions.
Studies in ES cells have revealed that self-renewal in these cells is regulated by an
interconnected regulatory circuit consisting of many factors, including Oct4, Sox2, and
Nanog, rather than by a single molecule50. Similarly, REST was found to be a part of the
interconnected network regulating ES cell self-renewal and pluripotency50–52. This suggests
that self-renewal in GSCs, as well as in normal neural stem cells, might be controlled by a
circuit, in which there is constant cross-talk between the regulators of self-renewal and the
microenvironment (niche), producing a dynamic equilibrium; when individual regulators of
the circuit are influenced by the niche, the equilibrium is re-set. To understand GBM
tumorigenesis and to design a more appropriate targeted therapy for GBM than what is
currently available, it will be important to identify and characterize the other players in this
self-renewal circuit.
Supplementary Material
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Figure 1. (A) Patient glioblastoma-derived stem cells (GSCs) show varying REST levels
Western blotting assays of GSCs obtained from 10 human GBM patient specimens showed
varying levels of REST, Sox2 and YKL-40 proteins. Actin was used as an internal control.
(B) Comparison of REST expression at the protein and transcript levels indicated that REST
protein levels do not correspond to Rest transcript levels (left panel). A scatter plot is also
shown (Right panel, Rsq=0.04). (C) Western blot based quantification of REST protein
levels in GSCs treated with either the proteasomal inhibitor (MG132) or solvent (DMSO)
indicated that REST protein is sensitive to proteasomal degradation in most of the GSC
lines.
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Figure 2. High REST protein expression correlates with stemness markers in GSCs
(A) Expression of REST, Nestin, Bmi1, Sox2, and YKL40 in two HR-GSCs (HR-GSC1 and
HR-GSC2) and one LR-GSC were determined by Western blotting assays. Actin was used
as an internal control. (B) Immunofluorescence analysis of the two HR-GSCs and one LR-
GSC shows a distinct pattern of expression of Sox2, and YKL-40. The bar in the figures
represents 50 micron. (C) HR-GSCs (HR-GSC1 and HR-GSC2) show higher neurosphere-
formation ability compared to LR-GSCs.
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Figure 3. REST controls self-renewal of GSCs
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(A, B) Rest loss-of-function experiments. Knockdown of REST with shRest (shNT as a
control) in HR-GSC1 (A) and HR-GSC2 (B) caused lowered expression of REST, higher
expression of the direct REST target neuronal beta-tubulin and lower expression of neural
stem cell self-renewal regulator Sox2 as determined by Western blotting assay (left panels),
and lowered self-renewal ability (right panels) (n=48). (C) REST gain-of-function
experiments. Expression of exogenous REST in LR-GSCs (expression of exogenous GFP
served as a control) caused decreased β-tubulin expression (left panel) and increased self-
renewal ability (right panel) (n=48).
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Figure 4. REST regulates survival in mice bearing GSC-mediated brain tumors
(A, B) HR-GSC1 and LR-GSC cells were transplanted into the brains of nude mice, the
mice were assayed for survival using Kaplan-Meier method (A) and histopathology of the
resulting tumors were examined by H&E staining (B) (n=7 mice per treatment group). HR-
GSC1 tumors produced shorter survival in mice than LR-GSC tumors and HR-GSC1 tumors
were more infiltrative than LR-GSC tumors, which showed circumscribed masses. Arrows
in the same direction indicate more infiltrative cells while those in the opposite direction
represent more restrictive structure. (C, D) Rest loss-of-function tumors. Stable lines of
HR-GSC1 (C) and HR-GSC2 (D) cells expressing either shREST or shNT were transplanted
into the brains of nude mice and mouse survival was compared. Knockdown of REST
produced increased survival in tumor-bearing mice generated by both lines (n=7 mice per
treatment group). (D) Rest gain-of-function tumors. LR-GSCs expressing either exogenous
REST or GFP were transplanted into the brains of nude mice, the mice were assayed for
survival. Additional REST converted LR-GSCs into more infiltrative tumors and decreased
survival in tumor-bearing mice (n=7 mice per treatment group).
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Figure 5. REST suppresses apoptosis in GSC-mediated brain tumors
(A–C) In vivo TUNEL assay indicating increased apoptosis in mouse tumors upon
knockdown of REST in HR-GSC1 (A) and HR-GSC2 (B). LR-GSCs showed reduced
apoptosis upon expression of exogenous REST compared to exogenous GFP control (C).
(D) quantification of in vivo TUNEL assays shown in A–C.
Kamal et al. Page 27













Kamal et al. Page 28













Figure 6. REST regulates invasion in GSC-mediated brain tumors
(A–C) Both HR-GSC1 (A)- and HR-GSC2 (B)-mediated tumors showed decreased invasion
upon shRest-treatment compared to control shNT-treatment. LR-GSC-mediated tumors
showed increased invasion upon expression of exogenous REST compared to GFP control
(C). Arrows in the same direction indicate more infiltrative cells while those in the opposite
direction represent more restrictive structure.P = pial layer. Bar = 50 micron.
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Table 1
Potential pathways regulated by REST in GSCs
Ingenuity Pathway Analysis of genome-wide expression profiles of GSCs with loss- and gain-of-function
manipulations.
Molecular and Cellular Functions
Name p-value # Molecules
Cellular Movement 1.99E-08 - 8.23E-03 63
Cellular Assembly and Organization 2.75E-08 - 7.77E-03 49
Cellular Development 4.61E-06 - 8.58E-03 80
Cell-To-Cell Signaling and Interaction 6.96E-06 - 8.58E-03 68
Cellular Growth and Proliferation 1.23E-05 - 8.62E-03 77
Physiological System Development and Function
Name p-value # Molecules
Tissue Development 2.75E-08 - 8.56E-03 75
Organismal Development 5.97E-07 - 8.77E-03 64
Cardiovascular System Development and Function 1.25E-06 - 8.02E-03 40
Connective Tissue Development and Function 1.79E-06 - 7.77E-03 35
Skeletal and Muscular System Development and Function 1.79E-06 - 8.77E-03 41
ID Associated Network Functions Score
1 Drug Metabolism, Endocrine System Development and Function, Lipid Metabolism 50
2 Cell-To-Cell Signaling and Interaction, Cellular Function and Maintenance, Drug Metabolism 32
3 Cellular Movement, Cell Morphology, Immune Cell Trafficking 30
4 Lipid Metabolism, Molecular Transport, Small Molecule Biochemistry 27
5 Cell Death, Cellular Development, Cellular Growth and Proliferation 26
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